Vivo Capital LLC Takes $13.10 Million Position in CytomX Therapeutics, Inc. $CTMX

Vivo Capital LLC bought a new position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) during the second quarter, HoldingsChannel reports. The firm bought 5,769,230 shares of the biotechnology company’s stock, valued at approximately $13,096,000. CytomX Therapeutics accounts for approximately 1.3% of Vivo Capital LLC’s holdings, making the stock its 13th biggest position. Vivo Capital LLC owned 0.07% of CytomX Therapeutics as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Marshall Wace LLP increased its stake in CytomX Therapeutics by 2,650.9% during the 2nd quarter. Marshall Wace LLP now owns 2,353,122 shares of the biotechnology company’s stock valued at $5,342,000 after purchasing an additional 2,267,583 shares in the last quarter. Invesco Ltd. bought a new stake in shares of CytomX Therapeutics during the second quarter worth about $32,000. Pursue Wealth Partners LLC acquired a new stake in shares of CytomX Therapeutics in the 2nd quarter worth about $33,000. Aspire Growth Partners LLC lifted its position in CytomX Therapeutics by 10.8% in the 2nd quarter. Aspire Growth Partners LLC now owns 102,254 shares of the biotechnology company’s stock valued at $232,000 after acquiring an additional 10,000 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in CytomX Therapeutics during the 2nd quarter valued at about $277,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Wall Street Zen downgraded CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. HC Wainwright upped their price target on CytomX Therapeutics from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. Cantor Fitzgerald started coverage on CytomX Therapeutics in a research note on Monday, September 22nd. They set an “overweight” rating and a $6.00 price objective on the stock. Barclays lifted their price objective on shares of CytomX Therapeutics from $3.50 to $6.00 and gave the stock an “overweight” rating in a report on Tuesday, October 21st. Finally, Weiss Ratings raised shares of CytomX Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $6.67.

CytomX Therapeutics Stock Down 2.0%

Shares of CTMX stock opened at $3.87 on Tuesday. The firm has a market cap of $655.69 million, a P/E ratio of 9.68 and a beta of 2.37. The company has a 50 day moving average of $3.69 and a 200-day moving average of $2.78. CytomX Therapeutics, Inc. has a 12-month low of $0.40 and a 12-month high of $4.62.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.05). CytomX Therapeutics had a net margin of 24.66% and a return on equity of 44.49%. The firm had revenue of $5.96 million for the quarter, compared to the consensus estimate of $11.50 million. As a group, equities analysts expect that CytomX Therapeutics, Inc. will post -0.05 EPS for the current year.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.